Based on the success of a recently concluded Stage II clinical trial, Vaxon Biotech plans to start Stage III trials of Vx-001, a vaccine that may be effective against triple-negative breast cancer. Stage III trials for breast cancer will begin in 2012-13 and Vaxon Biotech expects that a vaccine might be available for triple negative in 2020. Gee whiz! Hurry up, guys.
Read the somewhat thick news release here.
Post a Comment